Clinical Trial Detail

NCT ID	NCT03696784
Title	Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	UNC Lineberger Comprehensive Cancer Center
Indications	nodal marginal zone lymphoma B-cell lymphoma primary mediastinal B-cell lymphoma splenic marginal zone lymphoma MALT lymphoma mantle cell lymphoma diffuse large B-cell lymphoma follicular lymphoma
Therapies	Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK
Age Groups:	adult senior